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ABSTRACT
Background: The Generalized Anxiety Inventory (GAI) has been developed for use in the assessment of anxiety
symptoms in older adults ( 65 years), but previous validation work has not examined the psychometric
qualities of the instrument in relation to treatment. The objective of this study was to examine the performance
of the GAI for its internal reliability, convergent and divergent validity, and its sensitivity to treatment.
Methods: Elderly patients with generalized anxiety disorder (GAD) participated in a 10-week double-blind
study of duloxetine treatment for patients with GAD. Anxiety symptoms were assessed with the Hamilton
Anxiety Rating Scale (HAMA), the Hospital Anxiety and Depression Scale (HADS) anxiety and depression
subscales, and the GAI. Internal reliability of the GAI was assessed with Cronbach’s α. Correlations among
the HAMA, HADS, and GAI scores were analyzed to determine convergent and divergent validity. Patients
were also compared on remission status using recommended cut-off scores for the GAI.
Results: Patients with GAD, who were at least 65 years of age, were randomly assigned to double-blind
treatment with either duloxetine (N = 151) or placebo (N = 140) for 10 weeks acute therapy. The mean
change on the GAI was significantly greater with duloxetine compared with placebo treatment (−8.36 vs.
−4.96, respectively, p  0.001). The GAI demonstrated good internal consistency, good convergent and
divergent validity, but suggested cut-off values for caseness with the GAI did not correspond to remission
status as measured by the HAMA.
Conclusions: Within an elderly patient population with GAD, the GAI demonstrated sound psychometric
qualities and sensitivity to change with treatment.
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Introduction
As one of the most frequent anxiety disorders, the
hallmark of GAD is excessive and difficult to control
worry that occurs across a number of different con-
tent areas, such as interpersonal/family, work, fin-
ances, and minor events (Roemer et al., 1997). Not
surprisingly, the number of different life changes
and stressors associated with aging, such as retire-
ment, financial changes, and health concerns, result
in many elderly adults being particularly vulnerable
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to the development of GAD. In one epidemiological
study, among 2,136 elderly adults between the ages
of 65 and 96 years, 79% of the sample reported
worrying excessively during the previous month,
with 6.3% meeting the diagnostic criteria for GAD
(Golden et al., 2011). Similarly, in the National
Comorbidity Replication Survey (NCS-R), GAD
was one of the most prevalent psychiatric disorders
in 2,575 elderly adults; the 12-month prevalence
rate of GAD was 2.0% among the “young old,
ages 55–64 years,” 3.2% among the “mid-old, ages
65–74 years,” 1.7% among the “old-old, ages 75–
84 years,” and 0.9% among the “oldest-old, ages
greater than 85 years” (Byers et al., 2010).
A number of instruments have been used to
assess anxiety symptoms and disorders within the
elderly. While clinical trials typically rely on the
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clinician-based instrument, the HAMA (Hamilton,
1959), as a “gold standard” to assess the efficacy
of treatment, the length and complexity of this
instrument limits its practicality within other types
of clinical settings, which often rely on patient-
reported measures. In a recent review of measures
for the assessment of anxiety in the elderly,
the authors found that anxiety questionnaires
developed with a broader patient age population
are often applied to the elderly without additional
psychometric validation (Thiessen and Hunsley,
2012). Given that elderly patients may have
cognitive and physical conditions that can impact
how they respond to a questionnaire, assuming that
an instrument’s validity applies to the elderly may
be questionable without specific examination.
The need to develop a patient-reported
instrument to assess anxiety in elderly patients that
would incorporate the sensitivity of clinician-rated
scales, such as the HAMA, while considering the
needs of elderly patients led to the development
of the Geriatric Anxiety Inventory (GAI, Pachana
et al., 2007). The instrument was developed to be
sensitive to considerations pertinent to the elderly
patient population, such as brevity, ease of use,
and symptom profile. Specifically, the questionnaire
simplifies assessment so that patients indicate
“agree or disagree” rather than rating severity or
frequency of the symptom; there are no reverse
scoring items; and the content of the questions
focuses primarily on psychological symptoms of
anxiety as opposed to somatic symptoms that
may occur as from medical or medicine-related
confounds.
Since its introduction, the GAI has been
translated into other languages (e.g. Marquez-
Gonzalez, 2012), and has been used to screen
for anxiety in elderly patients with medical
conditions (e.g. Parkinson’s disease, Matheson
et al., 2012), and in long-term care (Gerolimatos
et al., 2013). The initial psychometric validation
demonstrated reliability and sensitivity for the
assessment of anxiety among elderly patients using
a psychogeriatric service. Despite its promising
characteristics, the properties of the GAI have
not been studied for its sensitivity to change in a
controlled treatment setting. Therefore, the GAI
was included as an exploratory objective in a
placebo-controlled clinical trial that studied the
efficacy of duloxetine (a serotonergic noradrenergic
reuptake inhibitor) compared with placebo in older
adults (65 years of age) who were diagnosed
with GAD. Results from this trial showed that
duloxetine was an efficacious treatment, and details
of the trial have been published elsewhere (Alaka
et al., 2014). Using the GAI data from this
clinical trial, additional psychometric validation
for the instrument was undertaken and reported
here.
Methods and materials
The study was conducted in 47 sites across 9
countries that included Argentina, Austria, Canada,
Germany, Mexico, Poland, Spain, the United
Kingdom, and the United States. Institutional
Review Boards at each site approved the protocol,
which was developed in accordance with the
ethical guidelines of Good Clinical Practice and
the Declaration of Helsinki. All patients provided
written consent after the study was explained,
and their questions were answered before any
study procedures were initiated. The trial was
publically registered at clintrials.gov (identifier:
NCT01118780).
Participants
Male and female outpatients were included if
they were at least 65 years of age and met
criteria for GAD as defined by the Diagnostic and
Statistical Manual of Mental Disorders, Fourth
Edition-Text Revised (DSM-IV TR) (American
Psychiatric Association, 2000) and assessed by
the Mini International Neuropsychiatric Interview
(Sheehan et al., 1998). Each patient was required to
have GAD with at least moderate illness severity
as defined by the following: a Clinical Global
Impressions of Severity of Illness (CGI-S) (Guy,
1976) score 4; Covi Anxiety Scale (Lipman et al.,
1981) score  9; no item score >3 on the Raskin
Depression Scale (RDS) (Raskin et al., 1969); CAS
total score > RDS total score; and a Hospital
Anxiety and Depression Scale (HADS) (Zigmond
and Snaith, 1983) anxiety subscale score 10. A
patient was also required to have a Mini-Mental
State Examination (MMSE) (Folstein et al., 1975)
score of 24.
The main exclusion criteria were as follows: a
primary Axis I psychiatric diagnosis other than
GAD; benzodiazepine use in the prior 14 days
before randomization; serious risk for harm to self
or others; history of alcohol or any psychoactive
substance abuse or dependence (as defined in the
DSM-IV TR) within the past 6 months; positive
urine screen for any substances of abuse; or
the presence of a medical condition that could be
potentially worsened by duloxetine.
Study design
The study was a multi-center, randomized, double-
blind, placebo-controlled, flexible-dose, parallel
group trial that consisted of three study periods:
screening/ washout period (up to 30 days), 10-week
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therapy period; and an optional 2-week taper-off
drug period. Study visits were conducted at weeks
2, 4, 7, and 10. Patients were randomly assigned
to receive treatment with duloxetine or placebo
once daily (QD) in a 1:1 ratio. For the duloxetine
group, treatment was initiated with 30 mg QD for
at least two weeks. After these two weeks, the dose
could be increased by 30-mg increments up to a
maximum dose of 120 mg. Dose adjustments were
based on the investigator’s judgment and the degree
of clinical improvement. All patients were required
to maintain a minimum dose of 30 mg to remain in
the treatment phase of the study.
Measurements
GER I A T R I C A NXIETY INVENTORY
The GAI is a 20-item self-report measure that
uses an agree/disagree response format, with the
number of agree responses added into a total score.
The content of the majority of items is focused
primarily on psychological anxiety, such as “I worry
a lot of the time,” “I can’t help worrying about
trivial things,” “I think of myself as a worrier,” “I
miss out on things because I worry too much,”
although there are a few items that contained
somatic references, such as, “I get an upset stomach
due to my worrying,” “ I often feel shaky inside,”
and “I often feel that I have butterflies in my
stomach” (see Pachana et al., 2007 for full item
descriptions).
VA LI DA T I ON M EASURES
The primary outcome measure for the study was
the clinician-rated HAMA, which was administered
using the Structured Interview Guide for the
Hamilton Anxiety Rating Scale (Shear et al., 2001).
The HAMA total score is the sum of the ratings for
each of the 14 items, with item 1 being “anxiety
mood” and item 2 being “tension” as the core
symptoms of GAD. The HAMA has also been
examined based on factor structure, with a HAMA
psychic factor consisting of the total of items 1–6
and 14 and a somatic factor consisting of the total
of items 7–13. Patients also completed the HADS,
which is a 14-item questionnaire that consists of
an anxiety subscale (HADS-A) and a depression
subscale (HADS-D). Each subscale is the sum of
seven questions and the score ranges from 0 to
21, with higher scores indicating greater severity.
Overall improvement during the study was assessed
by the clinician using the Clinical Global Impression
of Improvement (CGI-I) and by the patient with the
Patient Global Impression of Improvement (PGI).
Both scales are scored from 1 to 7 with 1 = “very
much better,” 4 = “no change,” and 7 = “very
much worse” (Guy, 1976).
Statistical methods
Psychometric evaluation for the GAI was to assess
reliability, convergent and divergent validity, known
group validation, and sensitivity to treatment. To
assess reliability, an internal consistency estimate
was calculated from the GAI individual items using
Cronbach’s α. Convergent validation was assessed
by Pearson correlation coefficients between the GAI
total score and the HAMA total score, HAMA
anxious mood rating (item 1), HAMA tension
rating (item 2), HAMA psychic score, and HAMA
somatic score. Divergent validation was assessed by
the correlation between the GAI and the HADS-D
scores at baseline and at endpoint.
The HAMA was also used as an external criterion
measure. Patients were assessed as meeting criteria
for remission at endpoint if their HAMA total score
was 7 (Matza et al., 2010). Patients were assessed
for their status as a “case” based on the GAI
total score, with a GAI total score <10 indicating
“noncaseness” and GAI total score  10 indicating
“caseness.” The percentage of patients meeting
HAMA remission criteria was compared based on
their GAI caseness status to determine whether the
GAI category could discriminate between patients
who were assessed as being in remission.
The GAI sensitivity to change was measured
by assessing the mean change in GAI total score
from baseline to 10 weeks for patients who had
received duloxetine compared with patients who
had received placebo. The analysis model was based
on a mixed-effects repeated-measures (MMRM)
model with terms for treatment, pooled investigative
site, visit, treatment-by-visit interaction, baseline
GAI total score, and the baseline GAI total
score-by-visit interaction. Treatment differences
were also analyzed using an ANCOVA model
based on the last observation carried forward
(LOCF) method with terms for treatment, pooled
investigative site, age, and baseline GAI total score.
Pearson correlation coefficients were also computed
between change in GAI total score across treatments
and the CGI-I and PGI-I ratings.
Results
The majority of patients were female (77.7%)
and the mean age of the patient population was
71.6 years. Of the 291 patients who were enrolled
in the study, 220 completed the study. There
were no differences between treatment groups
in demographics or baseline illness characteristics
(Table 1, data not shown by treatment). Using the
baseline GAI item responses, the internal reliability
of the GAI was calculated as 0.81 based on
Cronbach’s α.
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Table 1. Patient demographics and baseline illness
characteristics
C H A R A C T E R I S T I C T O T A L (N = 291)
........................................................................................................................................................
Age (yrs); mean (SD) 71.6 (5.2)
% Female 77.7%
Race (%)
Caucasian 85.6%
African–American 1.7%
Other 12%
HAMA total score; mean (SD) 24.5 (6.7)
HADS anxiety subscale (SD) 13.7 (3.2)
HADS depression subscale (SD) 7.4 (4.1)
GAI total score; mean (SD) 14.3 (4.1)
Abbreviations: SD, standard deviation; HAMA, Hamilton Anxiety
Rating Scale; HADS, Hospital Anxiety and Depression Scale;
GAI, Geriatric Anxiety Inventory.
Convergent/divergent validation
Baseline and endpoint scores were used to establish
the convergent validation of instruments (Table 2).
The GAI total score was correlated with the HAMA
total score, factor scores, and individual items
as well as the anxiety and depression subscales
of the HADS. At both time points, the GAI
total score was most highly correlated with the
HADS-A subscale scores. Overall, the correlations
were higher at endpoint compared with baseline.
Between the HADS-A and the HADS-D subscales,
the GAI demonstrated a stronger association with
the HADS-A subscale. The correlations between
the GAI total and the clinician-rated HAMA total
scores were lower compared with the GAI and the
HADS subscales.
Known groups’ validation
Endpoint scores were examined to determine
whether patients met criteria for remission of
their GAD based on the HAMA total score. The
original discrimination work conducted by Pachana
et al. (2007) suggested that a GAI total score of
˃ 10 represents “caseness” or clinical significance
whereas scores < 10 are indicative of nonclinical
cases. The status of remission defined by HAMA
total score was then examined by the status of cases
by the GAI total score (Figure 1). As can be seen,
whereas, scores  10 on the GAI were sensitive to
cases of nonremission as indicated by the HAMA
endpoint score, the results for GAI scores < 10 were
more equivocal. More than half of the patients with
lower GAI score were categorized as nonremitted
by their endpoint HAMA total score.
Sensitivity to change
Patients who were treated with duloxetine
experienced significantly greater improvement as
measured by the GAI total score starting at
week 4 and continuing throughout the study (p
ranges from  0.01 to 0.001) (Figure 2). In
both the MMRM and LOCF analyses, the mean
difference in improvement for patients who received
duloxetine was approximately 3 points greater
compared with patients who received placebo. As
noted, the correlations between the GAI, HAMA
and associated measures, and the HADS were
also higher at endpoint, indicating that changes
in the GAI were strongly correlated with changes
on other disease measures. Similarly, the change
in GAI total score also correlated similarly with
global assessment of improvement as measured by
the clinician, (CGI-I, r = 0.46, p  0.05) and by
the patient (PGI-I, r = 0.47, p  0.05).
Discussion
The results from the current study support the use
of the GAI as a measure of severity of anxiety
symptoms within an older adult population with
GAD. At baseline, given the inclusion criteria,
patients were required to have an illness of at least
moderate severity, and the mean scores on the
HAMA and HADS-A were consistent with this
range of severity (Zigmond and Snaith, 1983; Matza
et al., 2010). Based on these values, then, a mean
GAI score of approximately 14 could be interpreted
as also reflecting at least moderate illness severity.
From a content validity perspective, the GAI has
been shown to have four main factors: central
nervous system hyperarousal, excessive worry,
difficulty making decisions, and gastrointestinal
symptoms (Diefenbach et al., 2014), and good
internal consistency, which was also reflected by
the strong reliability coefficient within the present
trial.
Overall, the GAI demonstrated good convergent
validation as shown by its correlations with the
total scores as measured by the HADS-A, and
to a lesser extent, the HAMA. At baseline, the
GAI was more highly correlated with the HADS-A
subscale compared with the HAMA, which support
that these two instruments were tapping into the
same construct and reflect the patient’s view of
the severity of the anxiety illness. In comparison,
the lower correlations with the HAMA total score
reflect perhaps different sensitivity of the instrument
due to methodology as well as the content. In the
HAMA, the rating is based on clinical judgment
in which the frequency and severity of symptoms
provide a foundation for the scores. In addition,
both the HADS-A subscale and the GAI have item
content that focus predominantly on psychological
symptoms (difficulty concentrating, worrying) as
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Table 2. Correlations of the GAI total score with Hamilton anxiety rating scale and hospital anxiety and
depression subscales at baseline and at endpoint
BASELINE CORRELATION ENDPOINT CORRELATION
M E A S U R E S
W I T H GAI TOTAL
SCORE (N = 291)
W I T H GAI TOTAL SCORE
(N = 275)
............................................................................................................................................................................................................................................................................................................................
HAMA total score 0.25∗ 0.55∗
HAMA “anxious mood” item 0.12∗ 0.46∗
HAMA “tension” item 0.12∗ 0.49∗
HAMA psychic factor score 0.18∗ 0.51∗
HAMA somatic factor score 0.23∗ 0.50∗
HADS anxiety subscale 0.51∗ 0.70∗
HADS depression subscale 0.28∗ 0.48∗
Abbreviations: HAMA, Hamilton Anxiety Ratings Scale; HADS, Hospital Anxiety and Depression Scale.
∗p  0.05.
Figure 1. (Color online) Least squares mean change in GAI total score from baseline by visit and by last observation carried forward
method (LOCF) for patients treated with either duloxetine or placebo.
Figure 2. Percent of patients whose HAMA total scores at endpoint met criteria for remission or nonremission by GAI total score “caseness”
category at endpoint. Remission for HAMA total score was deﬁned as endpoint score 7.
opposed to the mixture of psychic and somatic
symptoms in the HAMA scale. At endpoint,
the correlations between the GAI and the other
anxiety measures were stronger, which may in
part be due to less restriction of range in the
total scores. At baseline, patients had to have at
least moderate severity whereas endpoint scores
could range from remitted to severe anxiety. The
correlation at endpoint between the GAI and the
HADS-A subscale was particularly strong (r =
0.70), supporting the convergence between these
measures.
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In evaluating the pattern for divergent pattern
of correlations among the measures of anxiety
and depression, the relationship between GAD
and major depressive disorder (MDD) must be
considered as these conditions are frequently
comorbid, especially among the elderly (Byers
et al., 2010). The overlap in these independent
but associated constructs can make it difficult
to determine the ability of an instrument to
distinguish between these illnesses. One strength,
however, of the present clinical study is that
patients with a diagnosis of MDD were excluded
from participation, which is reflected by a mean
HADS-D subscale total score that is below the
threshold for depression using this measure. Thus,
within this more uniform sample, the GAI was
able to demonstrate greater divergence between the
anxiety and depression construct as measured by
its stronger correlation with the HADS-A subscale
compared with its correlation with the HADS-
D subscale. As with the HADS-A subscale, the
correlations between the GAI and the HADS-D
subscale increased at endpoint reflecting potentially
a wider range of depression scores at endpoint
despite the initial exclusion criteria.
Since its introduction, the GAI has been
primarily studied as a screening instrument within
older adults for the purpose of identifying
individuals who may need a more thorough
evaluation and treatment for an anxiety diagnosis.
In the initial validation sample, the suggested cut-off
to distinguish between clinical cases and noncases
was a GAI total score of 10. More recent work
with a sample of older adults receiving home health
services supported a score of 9 as the optimal cut-
off for sensitivity and specificity in distinguishing
between clinical cases (Diefenbach et al., 2009).
On the other hand, in a sample of patients with
chronic obstructive pulmonary disease, the optimal
threshold was 2 or 3, reflecting the overall lower
base rate for clinical anxiety within this study
(Cheung et al., 2012).
In the present study, the cut-off was validated
against the external criterion of remission following
treatment as defined by the HAMA clinician rating
total score at endpoint. Within this psychiatric
population, patients who were identified as “cases”
by the GAI were likely cases as identified by
the clinician measure of the HAMA; however,
approximately half of the “noncases” by the GAI
were still symptomatic using the HAMA total score
at endpoint. However, as indicated above, one
criticism of using the HAMA with older adults is its
emphasis on somatic symptoms that may actually
be due to other comorbid medical conditions or
medications. The HAMA “nonremitted” status
could reflect symptoms associated with these
confounds. As a screening instrument, the cut-off
scores of potential “caseness” will therefore vary
according to the targeted patient population, but
the sensitivity to change in the GAI scores within the
psychiatric population suggests that the instrument
may also serve as a useful tool for monitoring the
outcome of treatment.
In summary, the GAI represents a brief, patient-
reported outcome measure that has been designed
to assess anxiety symptom severity using a format
and structure to enhance its ease of use with the
older adult population. As a screening instrument,
a number of studies have provided evidence of its
utility within populations of particular relevance
for the older adult population, such as cognitive
impairment (Diefenbach et al., 2013). The present
study builds upon this foundation by providing
the psychometric characteristics in a well-defined
population of older adults with GAD and by
demonstrating its usefulness as a measure of change
with an established treatment.
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